Aprea Therapeutics to Present at Major Investment Conference
Aprea Therapeutics, Inc. (NASDAQ: APRE) is an innovative biopharmaceutical company focused on precision oncology through synthetic lethality. Known for its groundbreaking methods in treating solid tumors, Aprea will engage with investors at the upcoming H.C. Wainwright Annual Global Investment Conference.
Conference Overview
During this esteemed event, Oren Gilad, Ph.D., the President and CEO of Aprea, will provide an insightful corporate update. The conference spans three days, offering Aprea a valuable opportunity to connect with institutional investors and highlight its potential for the future.
Event Timing and Location
The conference will take place from September 9-11. Attendees can look forward to gaining insights into Aprea's strategic positioning in the biopharmaceutical sector, particularly within oncology.
Accessing the Presentation
Aprea is pleased to announce that the presentation will be available on-demand, starting at 7:00 A.M. Eastern Time on the first day of the conference. Those interested can view the presentation for a full 90 days following the event.
Individual Investment Meetings
In addition to the main presentation, Aprea's management team is eager to engage in meaningful discussions with investors. They will be available for one-on-one meetings, allowing for in-depth conversations about their pipeline and ambitious goals.
About Aprea Therapeutics
Aprea Therapeutics is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania. The company is dedicated to synthetic lethality, aiming to offer new treatment options for cancer patients. Their flagship initiative is ATRN-119, a development program for a small molecule ATR inhibitor targeting solid tumors.
Advancements in Innovative Therapies
Furthermore, Aprea has recently launched clinical trials for APR-1051, an oral small molecule WEE1 inhibitor. This progress underscores Aprea's commitment to delivering transformative therapies that can significantly enhance patient outcomes in oncology.
Keeping Investors Updated
Investors can stay informed about Aprea's latest developments by visiting their investor relations website, which serves as an essential resource for material non-public information and compliance with relevant regulations.
Contact Information
For investor inquiries, Mike Moyer from LifeSci Advisors is available to assist. Additionally, media representatives Ignacio Guerrero-Ros, Ph.D., and David Schull from Russo Partners are on hand to provide further information, ensuring that all stakeholders remain informed.
Frequently Asked Questions
What is Aprea Therapeutics focused on?
Aprea Therapeutics specializes in precision oncology through synthetic lethality, particularly targeting the treatment of solid tumors.
Who will present at the upcoming conference?
Oren Gilad, Ph.D., the President and CEO of Aprea Therapeutics, will be the presenter at the conference.
When is the H.C. Wainwright Annual Global Investment Conference?
The conference is scheduled for September 9-11.
How can I access the presentation?
The presentation will be available on-demand starting at 7:00 A.M. (ET) on September 9, 2024, and can be viewed for 90 days thereafter.
How can investors request meetings?
Investors interested in one-on-one meetings should reach out to their conference representative to arrange a session.